Publications.
Modeling the Cost-Utility of Treatment Sequences for Multiple Sclerosis
Distributional consequences of including survivor costs in economic evaluations distributional consequences of survivor costs in economic evaluations
Quality of life among people living with HIV in England and the Netherlands: a population-based study
The Mental Health Quality of Life Questionnaire (MHQoL): development and first psychometric evaluation of a new measure to assess quality of life in people with mental health problems
Good Days and Bad Days: Measuring Health-Related Quality of Life in People With Epilepsy
Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine
Methodological Challenges in the Economic Evaluation of a Gene Therapy for RPE65-Mediated Inherited Retinal Disease: The Value of Vision
Burden of providing informal care for patients with atrial fibrillation
A randomised comparison of the effect of haemodynamic monitoring with CardioMEMS in addition to standard care on quality of life and hospitalisations in patients with chronic heart failure
Ravulizumab for paroxysmal nocturnal haemoglobinuria: a Single Technology Assessment
Pharmaceutical pricing: what is reasonable?
Evaluation of the performance of algorithms mapping EORTC QLQ-C30 onto the EQ-5D index in a metastatic colorectal cancer cost-effectiveness model
Early cost-utility analysis of tissue-engineered heart valves compared to bioprostheses in the aortic position in elderly patients
Summarizing patient preferences for the competitive landscape of multiple sclerosis treatment options
Evaluating the Effectiveness and Cost-Effectiveness of Seizure Dogs in Persons With Medically Refractory Epilepsy in the Netherlands
Protocol: comparing the effectiveness and cost-effectiveness of self-management interventions in four high-priority chronic conditions in Europe (COMPAR-EU): a research protocol
Bioprosthetic aortic valve replacement in elderly patients: Meta-analysis and microsimulation
Severity-Adjusted Probability of Being Cost Effective
Is verlies winst? Stoppen met TNF-α-blokkers
